SECONDARY MYELOFIBROSIS
Clinical trials for SECONDARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for SECONDARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a drug make stem cell transplants safer for myelofibrosis patients?
Disease control OngoingThis study tests whether giving the drug ruxolitinib before, during, and after a donor stem cell transplant can help prevent graft-versus-host disease (GVHD) in people with myelofibrosis. About 53 adults with intermediate- or high-risk myelofibrosis will receive ruxolitinib to re…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New hope for rare bone marrow cancer: decitabine trial shows promise
Disease control OngoingThis study tested a drug called decitabine in 21 people with myelofibrosis, a rare bone marrow cancer that causes scarring and severe anemia. The goal was to see if the drug could improve blood counts and reduce the need for transfusions. Decitabine works by reactivating genes th…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New CMV strategy aims to protect stem cell transplant patients from dangerous infection
Disease control OngoingThis study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…
Matched conditions: SECONDARY MYELOFIBROSIS
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC